General Information of the Drug (ID: M6APDG02316)
Name
Ro 41-5253
Synonyms
Ro-415253; Ro415253; LG629
    Click to Show/Hide
Status
Investigative
Structure
Formula
C28H36O5S
InChI
1S/C28H36O5S/c1-5-6-7-8-9-15-33-25-19-26-24(28(3,4)14-16-34(26,31)32)18-23(25)20(2)17-21-10-12-22(13-11-21)27(29)30/h10-13,17-19H,5-9,14-16H2,1-4H3,(H,29,30)/b20-17+
InChIKey
JEIWQRITHXYGIF-LVZFUZTISA-N
PubChem CID
5312120
TTD Drug ID
D0JQ1D
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Retinoic acid receptor alpha (RARA)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Retinoic acid receptor alpha (RARA) is a therapeutic target for Ro 41-5253. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Ro 41-5253 through regulating the expression of Retinoic acid receptor alpha (RARA). [1], [2]
References
Ref 1 FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N(6)-Methyladenosine RNA Demethylase. Cancer Cell. 2017 Jan 9;31(1):127-141. doi: 10.1016/j.ccell.2016.11.017. Epub 2016 Dec 22.
Ref 2 Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58. doi: 10.2174/1381612003401415.